AI Summary Scores: Intraday / Swing / Long scores are synthesized from multi-factor analysis for each timeframe. They summarize current conditions discussed in the report and do not constitute trading recommendations.
Intraday Trend Score: A 0–100 composite from the Trend Explorer™ analytics engine used for ranking and comparison. It describes current conditions and is not a forecast.
Trend Status: A rules-based label (Bullish / Mixed / Bearish) derived from signal confluence (trend structure, momentum, and positioning). It indicates alignment, not expected return.
Last
$29.33
−$0.66 (−2.20%) 4:00 PM ET
After hours$29.35
+$0.02 (+0.07%) 4:06 PM ET
Prev closePrevC$29.99
OpenOpen$29.92
Day highHigh$29.92
Day lowLow$29.08
VolumeVol196,123
Avg volAvgVol334,028
On chart
Interval
Intervals apply to 1D & 5D.
Intervals apply to 1D & 5D.
Scale: Linear
Overlays
Panels
Style
Scale: Linear
Presets
Tools
Tickers only (no ^ indexes). Add up to 5.
Mkt cap
$1.70B
Sector
Healthcare
AI report sections
MIXED
OCS
Oculis Holding AG
Oculis shows firm upward price momentum over 3–12 months with the latest close near the upper end of its 52-week range and above key moving averages. Technical indicators highlight multiple bullish breakout and momentum signals but also flag an overbought RSI that may indicate near-term exhaustion risk. The balance sheet appears equity-heavy with ample current assets relative to current liabilities while short interest remains very low despite an elevated short-volume ratio in recent trading.
AI summarized at 6:27 PM ET, 2025-12-06
AI summary scores
INTRADAY:68SWING:72LONG:60
Volume vs average
Intraday (cumulative)
−38% (Below avg)
Vol/Avg: 0.62×
RSI
69.02(Strong)
Strong (60–70)
0255075100
MACD momentum
Intraday
-0.03 (Weak)
MACD: -0.03 Signal: -0.00
Short-Term
-0.10 (Weak)
MACD: 1.19 Signal: 1.30
Long-Term
-0.04 (Weak)
MACD: 2.49 Signal: 2.53
Intraday trend score
52.46
LOW44.46HIGH75.46
Latest news
OCS•12 articles•Positive: 12Neutral: 0Negative: 0
PositiveGlobeNewswire Inc.• Na
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG announced the appointment of Katie Kazem as Chief Legal Officer, bringing over 15 years of experience in life sciences corporate and securities law. The appointment comes as the company advances three late-stage clinical assets, including Privosegtor in registrational trials and OCS-01 eye drops with Phase 3 results expected in Q2 2026.
The appointment of an experienced CLO with strong track record in life sciences strengthens corporate governance and legal capabilities. The company is advancing multiple late-stage assets toward important clinical and regulatory milestones, demonstrating operational momentum and progress in its pipeline development.
PositiveGlobeNewswire Inc.• Not Specified
Oculis Appoints Katie Kazem as Chief Legal Officer
Oculis Holding AG announced the appointment of Katie Kazem as Chief Legal Officer, bringing over 15 years of experience in life sciences corporate and securities law. The appointment comes as the company advances three late-stage clinical assets, including Privosegtor in registrational trials and OCS-01 eye drops with Phase 3 results expected in Q2 2026.
The appointment of an experienced CLO with 15+ years in life sciences law strengthens corporate governance and regulatory capabilities. The company is advancing three differentiated late-stage assets toward important clinical milestones, with Phase 3 results expected in Q2 2026, demonstrating significant momentum in its pipeline development.
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Oculis presented positive Phase 2 trial results for Privosegtor, showing improved visual acuity and preservation of retinal ganglion cells in acute optic neuritis patients at the ECTRIMS 2025 Congress.
Company reported promising clinical trial results demonstrating potential breakthrough in treating optic neuritis, with significant improvements in visual function and neuroprotection
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
Oculis presented positive Phase 2 trial results for Privosegtor, a potential neuroprotective treatment for acute optic neuritis, showing improved visual acuity and preservation of retinal ganglion cells at the ECTRIMS 2025 Congress.
Company reported promising clinical trial results demonstrating potential breakthrough in treating optic neuritis, with significant improvements in visual function and a favorable safety profile
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
Oculis, in collaboration with EURETINA, announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award, honoring an exceptional postgraduate scholar in retinal research who is studying neuronal excitability in retinal ganglion cells.
Company is promoting scientific research, supporting young researchers, and maintaining a positive legacy through an award named after a former chief scientific officer
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
Oculis, in collaboration with EURETINA, announced Dr. Prithvi Ramtohul as the winner of the 2025 Ramin Tadayoni Award for his significant contributions to retinal research and imaging.
Company is promoting scientific research, honoring a former colleague, and supporting the next generation of ophthalmologists through an award
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis to Participate in Upcoming September Investor Conferences
Oculis, a global biopharmaceutical company, announced management participation in several healthcare investor conferences in September 2025, including Wells Fargo, H.C. Wainwright, Baird, Pareto Securities, and Leerink Partners events.
Company is actively engaging with investors, presenting at multiple conferences, and showcasing its clinical pipeline across different healthcare events
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis to Participate in Upcoming September Investor Conferences
Oculis Holding AG announced its management will participate in several healthcare investor conferences in September 2025, including Wells Fargo, H.C. Wainwright, Baird Global Healthcare, Pareto Securities, and Leerink Partners conferences.
Company is actively engaging with investors, presenting at multiple conferences, and showcasing its clinical pipeline across different healthcare events
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
Oculis has appointed two renowned medical experts, Mark Kupersmith and Sebastian Wolf, as Chief Medical Advisors to support their ophthalmology and neuro-ophthalmology research programs, following promising clinical trial results for their drug candidates OCS-01 and Privosegtor.
OCSOCSAWophthalmologyneuro-ophthalmologyclinical trialsmedical advisorsdrug development
Sentiment note
Company is expanding its leadership team with world-renowned experts, has achieved significant progress in clinical trials, and is positioning itself as a potential leader in ophthalmology and neuro-ophthalmology research
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
Oculis has appointed two renowned medical experts, Mark Kupersmith and Sebastian Wolf, as Chief Medical Advisors in Neuro-Ophthalmology and Ophthalmology, respectively, following promising clinical trial results in optic neuritis and diabetic macular edema treatments.
OCSOCSAWophthalmologyneuro-ophthalmologyclinical trialsmedical advisorsdrug development
Sentiment note
Company is expanding its leadership team with world-renowned experts, has achieved significant pipeline progress, and demonstrated promising clinical trial results in multiple ophthalmological treatments
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025, with CFO Sylvia Cheung presenting a corporate update and President of R&D Snehal Shah participating in a panel discussion on retinal disorders.
Company is actively presenting at a professional conference, showcasing its ongoing research and development in ophthalmic conditions
PositiveGlobeNewswire Inc.• Oculis Holding Ag
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
Oculis Holding AG will participate in the H.C. Wainwright 5th Annual Ophthalmology Virtual Conference on August 13, 2025, with CFO Sylvia Cheung presenting a corporate update and President of R&D Snehal Shah participating in a panel discussion on retinal disorders.
Company is actively presenting at a professional conference, showcasing its ongoing research and development in ophthalmic treatments
News and sentiment labels describe article tone and are provided for research purposes only. They are not trading recommendations or forecasts.
Trade Ranks App
Trade Ranks, LLC is not a registered investment adviser or broker-dealer. All rankings and AI reports are for informational and educational purposes only and are not personalized advice. Investing involves risk. Policy Portal
